Aidoc's CARE Model Named to TIME's Best Inventions List for 2026

Aidoc, an Israeli medical technology company, announced on Saturday that its artificial intelligence model, CARE, was selected for TIME magazine's Best Inventions of 2026 list. The inclusion places the software in the Medicine and Health category alongside other recognized technologies such as Anthropic's Claude Code and Lovable.

The CARE model analyzes medical imaging and clinical text to help physicians identify serious conditions at earlier stages. According to the company, the system flags examinations when it detects potentially urgent findings, allowing medical teams to prioritize those cases for review. This capability enables Aidoc to expand the range of conditions it can identify without developing a separate AI model for each specific disease.

Elad Walach, the company's CEO and co-founder, stated that the selection recognizes a major trend in healthcare. He described AI as an additional pair of eyes in almost every medical diagnosis. Walach noted that medical foundation models capable of detecting hundreds of diseases are among the developments that will affect the general population.

Aidoc was founded in 2016 by Walach, Michael Braginsky, and Guy Reiner. The platform analyzes medical imaging and other clinical data to alert doctors to potentially life-threatening conditions in real time. The company said its AI solutions have received clearance from the US Food and Drug Administration.

The technology is currently used across more than 150 healthcare systems in the United States and over 1,600 hospitals worldwide. The company stated that most hospitals in Israel also use the platform. TIME's annual list recognizes inventions based on originality, effectiveness, ambition, and impact.

Aidoc has raised more than $500 million since its founding. Investors have included General Catalyst, TLV Partners, Magma Emerge, Square Peg, SoftBank's Vision Fund 2, and NVentures, the venture capital arm of Nvidia. The company closed its most recent funding round in April 2026. That round totaled $150 million and was led by Goldman Sachs' growth investment division.